
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Korean research suggests long-term photochemotherapy using psoralen and ultra-violet A irradiation (PUVA) may cause several adverse effects, including skin cancer, especially squamous cell carcinoma.






